Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: A randomized trial

被引:23
|
作者
Pieramico, O
Zanetti, MV
Innerhofer, M
Malfertheiner, P
机构
[1] UNIV MAGDEBURG,DEPT GASTROENTEROL HEPATOL & INFECT DIS,D-39106 MAGDEBURG,GERMANY
[2] OSPED GEN,DEPT MICROBIOL,I-39012 MERANO,ITALY
关键词
D O I
10.1111/j.1523-5378.1997.tb00065.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives, it was our goal to evaluate the efficacy and safety and patient compliance with omeprazole-based dual and triple therapy for eradication of Helicobacter pylori in peptic ulcer disease. Materials and Methods. One hundred seventy-five consecutive patients with H. pylori infection and associated active peptic ulcer were included. H. pylori infection was assessed by rapid urease test and histological analysis. Patients were randomized among three treatments: group 1 (56 patients): omeprazole, 20 mg bid, and amoxicillin, 1 gm bid, for 2 weeks; group 2 (61 patients): omeprazole, 20 mg bid, plus amoxicillin, 1 gm bid, and metronidazole, 500 mg bid, for 1 week; and group 3 (58 patients): omeprazole, 20 mg bid, plus amoxicillin, 1 gm bid, and clarithromycin, 500 mg bid, for 1 week. Ulcer healing and cure of infection were evaluated at 4 to 6 weeks after cessation of therapy. Eradication rate was calculated per-protocol and by an intention-to-treat analysis. Results. At posttreatment endoscopy, duodenal ulcer was healed in 98.3% of patients. Eleven patients (6%) were lost to follow-up. H. pylori Infection was treated successfully in 55% (95% confidence interval [CI] = 41%-69%) of patients of group 1; 86% (95% CI = 77%-95%) of group 2 (p < .001 vs. group 1); and 93% (95% CI = 85%-100%) of group 3 (p < .001 vs. group I). On intention-to-treat analysis, eradication was 52%, 80%, and 86% in groups 1, 2, and 3, respectively. A good compliance was observed in more than 90% of patients of all groups. Side effects were reported by 7% of patients in group 1, 9% in group 2, and 11% in group 3. None of the patients stopped therapy because of side effects. Conclusions. Dual-therapy omeprazole-amoxicillin for 2 weeks is associated with significantly lower eradication rate than is 1-week omeprazole-based triple therapies. Triple therapy is well-tolerated and produces side effects similar to those of dual therapy. The highest cure rate of H. pylori infection was achieved with triple therapy of omeprazole, amoxicillin, and clarithromycin for 1 week.
引用
下载
收藏
页码:92 / 97
页数:6
相关论文
共 50 条
  • [41] Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection
    Wong, BCY
    Wong, WM
    Yee, YK
    Hung, WK
    Yip, AWC
    Szeto, ML
    Li, KF
    Lau, P
    Fung, FMY
    Tong, TSM
    Lai, KC
    Hu, WHC
    Yuen, MF
    Hui, CK
    Lam, SK
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (12) : 1959 - 1965
  • [42] Triple therapy with omeprazole, amoxicillin and clarithromycin in duodenal ulcer disease associated with Helicobacter pylori in Senegal
    Fall, F.
    Diagne, A.
    Ndiaye, B.
    Ndiaye, A. R.
    Diop, Y.
    Gning, S. B.
    Fall, K. Ba
    Gueye, N. M. Diagne
    Diallo, I.
    Mbaye, P. S.
    Debonne, J. M.
    JOURNAL AFRICAIN D HEPATO-GASTROENTEROLOGIE, 2011, 5 (01): : 28 - 32
  • [43] HELICOBACTER-PYLORI INFECTION IN PEPTIC-ULCER DISEASE
    BERSTAD, K
    BERSTAD, A
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 (07) : 561 - 567
  • [44] PEPTIC-ULCER DISEASE AND HELICOBACTER-PYLORI INFECTION
    GOODWIN, CS
    CARRICK, J
    CURRENT OPINION IN GASTROENTEROLOGY, 1991, 7 (01) : 108 - 115
  • [45] PEPTIC-ULCER DISEASE AND HELICOBACTER-PYLORI INFECTION
    VAIRA, D
    HOLTON, J
    MIGLIOLI, M
    MENEGATTI, M
    MULE, P
    BARBARA, L
    CURRENT OPINION IN GASTROENTEROLOGY, 1994, 10 (01) : 98 - 104
  • [46] HELICOBACTER-PYLORI INFECTION AND PEPTIC-ULCER DISEASE
    DOOLEY, CP
    CURRENT OPINION IN GASTROENTEROLOGY, 1993, 9 (01) : 112 - 117
  • [47] Peptic ulcer disease in children without Helicobacter pylori infection
    Demir, H
    Gürakan, F
    Özen, H
    Saltik, IN
    Yüce, A
    Özçay, F
    Koçak, N
    HELICOBACTER, 2002, 7 (02) : 111 - 111
  • [48] THE SAFETY OF DUAL THERAPY WITH CLARITHROMYCIN AND OMEPRAZOLE IN THE TREATMENT OF PATIENTS WITH DUODENAL-ULCER DISEASE-ASSOCIATED WITH HELICOBACTER-PYLORI INFECTION
    OLSON, C
    DEBARTOLO, M
    HIPPENSTEEL, R
    CRAFT, JC
    GASTROENTEROLOGY, 1995, 108 (04) : A183 - A183
  • [49] Prevalence of peptic ulcer disease and Helicobacter pylori infection in Khakassia
    Tsukanov, V. V.
    Vasyutin, A. V.
    Tonkikh, J. L.
    HELICOBACTER, 2017, 22
  • [50] PEPTIC-ULCER DISEASE AND HELICOBACTER-PYLORI INFECTION
    GOODWIN, CS
    WORSLEY, B
    CURRENT OPINION IN GASTROENTEROLOGY, 1992, 8 (01) : 122 - 127